COHR vs NOVT: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
COHR is the larger of the two ($36.29B market cap): the incumbent the market prices for continued execution (11.68x forward earnings, beta 2.23). NOVT is the smaller challenger ($3.97B), actually pricier on forward earnings (24.60x): more room to run, but more to prove. On the numbers, COHR leads on both counts: faster expected revenue growth (39% vs 15%) and a lower forward P/E (11.68x vs 24.6x). The case for NOVT rests on its own driver (Medical Solutions demand): if you believe in that, NOVT fits; if you believe in what the numbers show today, COHR does.
COHR vs NOVT: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | COHR | NOVT | What it tells you |
|---|---|---|---|
| Market cap | $36.29B | $3.97B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 11.68 | 24.60 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 38.15 | 79.58 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 2.23 | 1.70 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 17% of range | 7% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.20 | 2.45 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: COHR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how COHR and NOVT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COHR and NOVT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COHR and NOVT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Coherent Corp (COHR) do?
Coherent Corp, formerly II-VI and now trading as COHR on the NYSE, makes lasers, optical components, and high-speed transceivers used in AI data centers, telecom networks, industrial manufacturing, and semiconductors. Its largest and fastest-growing segment is Datacenter & Communications, which supplies the 800G and emerging 1.6T optical transceivers that connect GPUs and switches inside AI clusters, alongside a smaller Industrial segment covering lasers and materials.
What does Novanta (NOVT) do?
Novanta Inc. is a specialized technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems, which it sells to original equipment manufacturers (OEMs) in medical and advanced industrial markets worldwide. Its products include laser scanning and beam-steering systems, precision motors and encoders, machine-vision components, radio-frequency and surgical technologies, and other embedded devices that go inside customers' larger machines. The company organizes itself into two reporting segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and semiconductor and electronics manufacturing. Medical end markets represent a bit over half of revenue and advanced industrial the rest.
COHR vs NOVT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- COHR drivers: AI datacom transceiver demand; Transition to 1.6T optics.
- NOVT drivers: Medical Solutions demand; Automation and robotics.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: COHR has traded at a high earnings multiple (about 38 times trailing earnings even after the pullback), so any slowdown in AI capital spending or a demand air pocket can hit the stock hard, as the 37% three-month decline to November 20, 2026 showed. For NOVT, novanta trades at a high price-to-earnings multiple (about 80x trailing and 25x forward as of November 2026), so any shortfall in growth or margins can drive sharp share-price moves: the shares fell about 3% right after Q3 results, which came with a small cut to full-year adjusted EPS guidance and fourth-quarter EBITDA guidance below expectations, and ended about 25% lower over the month to November 20, 2026.
COHR or NOVT: which should you pick?
If the story you believe is COHR's (AI datacom transceiver demand), COHR is the more direct way to own it; if it is NOVT's (Medical Solutions demand), NOVT is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COHR and NOVT guides.
COHR vs NOVT: the full fundamentals
COHR. The gap between a trailing P/E near 38 and a forward multiple near 12 shows how much earnings growth the market and analysts are counting on, with consensus calling for EPS of about $10.37 in fiscal 2027 and $15.78 in fiscal 2028. The stock's slide from mid-October cut the market value from around $70 billion in the summer to about $36 billion on November 20, 2026, while 25 analysts hold a mean target near $372. The next report is expected around February 3, 2027, with consensus near $2.65 billion of revenue and $2.40 of EPS.
NOVT. Novanta still trades at a rich valuation, with a trailing price-to-earnings ratio near 80x and a forward multiple around 25x, down from about 30x forward in October after the shares fell roughly 25% in a month. GAAP earnings are held down by acquisition-related amortization, deal costs and stock compensation, so the company and analysts emphasize adjusted EPS, which beat consensus again in Q3 at $1.05 against $0.97 even as full-year adjusted EPS guidance was trimmed to about $3.69. Net debt of roughly $745 million after the Riverpoint deal is now part of the valuation picture.
Headline figures (approximate, November 2026): COHR shows revenue (ttm) ~$7.91B, ~+50% YoY in Q1 FY2027, q1 fy2027 revenue ~$2.37B, q1 fy2027 non-gaap eps ~$2.09 vs ~$1.97 consensus, net income (ttm) ~$962M, ~12% net margin; NOVT shows revenue (ttm) ~$1.09 billion, q3 fy2026 revenue ~$305 million (up ~23% YoY), q3 fy2026 adjusted eps ~$1.05 vs ~$0.97 consensus, margins (gross / operating / net) ~44% / ~12% / ~5%.
The bottom line: COHR vs NOVT
COHR and NOVT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined COHR and NOVT exposure against your real portfolio. It is not an investment adviser.
Wondering how COHR or NOVT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Coherent Corp
Ask Walnut's AI anything about COHR and see how it fits what you own.
FAQ
What is the difference between COHR and NOVT?
+
Coherent Corp, formerly II-VI and now trading as COHR on the NYSE, makes lasers, optical components, and high-speed transceivers used in AI data centers, telecom networks, industrial manufacturing, and semiconductors. Novanta Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is COHR or NOVT the better stock?
+
Neither is universally better. COHR is the larger incumbent; NOVT is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, COHR or NOVT?
+
On forward P/E (as of November 2026), COHR trades at 11.68x and NOVT at 24.60x, so COHR is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both COHR and NOVT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of COHR vs NOVT?
+
COHR: COHR has traded at a high earnings multiple (about 38 times trailing earnings even after the pullback), so any slowdown in AI capital spending or a demand air pocket can hit the stock hard, as the 37% three-month decline to November 20, 2026 showed. Analysts have started trimming targets, with B. Riley cutting to $297 from $345 and keeping a neutral rating. Revenue is concentrated among a small number of hyperscaler and networking customers, which creates order-timing and pricing risk. Heavy capacity spending has turned free cash flow deeply negative (about -$1.7 billion over the trailing twelve months) while debt has risen, and a $2 billion buyback would compete for the same cash, which adds risk if demand slows before the new lines are full. The optical components industry is cyclical and competitive, with pricing pressure from Chinese module makers and component rivals. The Industrial segment has been soft, and the company remains sensitive to macro conditions and semiconductor capital cycles. Execution on the 1.6T ramp and capacity expansion is not guaranteed. NOVT: Novanta trades at a high price-to-earnings multiple (about 80x trailing and 25x forward as of November 2026), so any shortfall in growth or margins can drive sharp share-price moves: the shares fell about 3% right after Q3 results, which came with a small cut to full-year adjusted EPS guidance and fourth-quarter EBITDA guidance below expectations, and ended about 25% lower over the month to November 20, 2026. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform; after Riverpoint, debt is about $894 million against about $149 million of cash, and GAAP profit margins are thin at about 5%, with Q3 GAAP net income of only about $2 million. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell COHR or NOVT; figures are approximate and dated (as of November 2026). Verify current data before investing.